Find Lisdexamfetamine Dimesylate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Vyvanse, 608137-33-3, Nrp-104, Lisdexamfetamine mesilate, Spd489, Tyvense
Molecular Formula
C17H33N3O7S2
Molecular Weight
455.6  g/mol
InChI Key
CETWSOHVEGTIBR-FORAGAHYSA-N
FDA UNII
SJT761GEGS

Lisdexamfetamine Dimesylate
A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.
1 2D Structure

Lisdexamfetamine Dimesylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide;methanesulfonic acid
2.1.2 InChI
InChI=1S/C15H25N3O.2CH4O3S/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16;2*1-5(2,3)4/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19);2*1H3,(H,2,3,4)/t12-,14-;;/m0../s1
2.1.3 InChI Key
CETWSOHVEGTIBR-FORAGAHYSA-N
2.1.4 Canonical SMILES
CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O
2.1.5 Isomeric SMILES
C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
SJT761GEGS
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Dimesylate, Lis-dexamfetamine

2. Dimesylate, Lisdexamfetamine

3. Elvanse

4. Lis Dexamfetamine Dimesylate

5. Lis-dexamfetamine Dimesylate

6. Lisdexamfetamine

7. Nrp 104

8. Nrp-104

9. Nrp104

10. Vyvanse

2.3.2 Depositor-Supplied Synonyms

1. Vyvanse

2. 608137-33-3

3. Nrp-104

4. Lisdexamfetamine Mesilate

5. Spd489

6. Tyvense

7. Nrp104

8. Spd-489

9. Lisdexamfetamine Dimesylate [usan]

10. Lisdexamfetamine Dimesilate

11. Sjt761gegs

12. Lisdexamphetamine Dimesilate

13. L-lysine-d-amphetamine Dimesylate

14. Lisdexamfetamine Dimethanesulfonate

15. (2s)-2,6-diamino-n-[(1s)-1-methyl-2-phenylethyl]hexanamide Dimethanesulfonate

16. Lis-dexamfetamine Dimesylate

17. Lisdexamfetamine Mesilate (jan)

18. Lisdexamfetamine Dimesylate (usan)

19. Lisdexamfetamine Mesylate

20. Nrp 104

21. Lisdexamfetamine Mesilate [jan]

22. (2s)-2,6-diamino-n-[(2s)-1-phenylpropan-2-yl]hexanamide;methanesulfonic Acid

23. Unii-sjt761gegs

24. Venvanse

25. (2s)-2,6-diamino-n-((1s)-1-methyl-2-phenylethyl)hexanamide Dimethanesulfonate

26. Lys-amp

27. Spd 489

28. Lys-d-amp

29. Elvanse (tn)

30. Vyvanse (tn)

31. Schembl678421

32. Chembl1201178

33. Dtxsid60209653

34. Lisdexamfetamine Dimesylate Solution

35. Bcp24044

36. Akos030254940

37. Lisdexamfetamine Mesilate [mart.]

38. Ldx

39. Lisdexamfetamine Mesilate [who-dd]

40. Lisdexamfetamine Dimesylate [vandf]

41. D04747

42. Lisdexamfetamine Dimethanesulfonate [mi]

43. Lisdexamfetamine Dimesylate [orange Book]

44. 137l333

45. Q27289243

46. (2s)-2,6-diamino-n-((1s)-1-methyl-2-phenylethyl)hexanamide Dimethanesulphonate

47. Hexanamide, 2,6-diamino-n-((1s)-1-methyl-2-phenylethyl), (2s), Dimethanesulfonate

48. Hexanamide, 2,6-diamino-n-((1s)-1-methyl-2-phenylethyl), (2s), Dimethanesulphonate

49. Ldx;lisdexamfetamine Mesilate;lisdexamfetamine Mesylate;nrp 104;nrp-104;spd 489

50. Lisdexamfetamine Dimesylate Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 455.6 g/mol
Molecular Formula C17H33N3O7S2
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count9
Rotatable Bond Count8
Exact Mass455.17599275 g/mol
Monoisotopic Mass455.17599275 g/mol
Topological Polar Surface Area207 Ų
Heavy Atom Count29
Formal Charge0
Complexity344
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameLisdexamfetamine dimesylate
Drug LabelVyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate....
Active IngredientLisdexamfetamine dimesylate
Dosage FormCapsule
RouteOral
Strength30mg; 50mg; 60mg; 40mg; 70mg; 20mg
Market StatusTentative Approval
CompanyMylan Pharms; Amneal Pharms; Roxane

2 of 4  
Drug NameVyvanse
PubMed HealthAmphetamine (By mouth)
Drug ClassesAmphetamine
Drug LabelVyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate....
Active IngredientLisdexamfetamine dimesylate
Dosage FormCapsule
RouteOral
Strength30mg; 50mg; 60mg; 40mg; 20mg; 70mg
Market StatusPrescription
CompanyShire Development

3 of 4  
Drug NameLisdexamfetamine dimesylate
Drug LabelVyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate....
Active IngredientLisdexamfetamine dimesylate
Dosage FormCapsule
RouteOral
Strength30mg; 50mg; 60mg; 40mg; 70mg; 20mg
Market StatusTentative Approval
CompanyMylan Pharms; Amneal Pharms; Roxane

4 of 4  
Drug NameVyvanse
PubMed HealthAmphetamine (By mouth)
Drug ClassesAmphetamine
Drug LabelVyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate....
Active IngredientLisdexamfetamine dimesylate
Dosage FormCapsule
RouteOral
Strength30mg; 50mg; 60mg; 40mg; 20mg; 70mg
Market StatusPrescription
CompanyShire Development

4.2 Drug Indication

Treatment of Attention Deficit Hyperactivity Disorder (ADHD)


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Central Nervous System Stimulants

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)


Dopamine Uptake Inhibitors

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Central Nervous System Stimulation [PE]; Central Nervous System Stimulant [EPC]

API SUPPLIERS

read-more
read-more

01

Veranova

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
Veranova

02

Noramco

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNoramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.

Flag U.S.A
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Noramco

03

Supriya Lifescience

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Supriya

04

Cohance Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Cohance

05

Fermion Oy

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
fermion

06

Temad Co

Iran

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTemad- We think of world-class quality.

Flag Iran
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Temad

07

Malladi Drugs & Pharmaceuticals Li...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMalladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Malladi

08

Moehs Iberica

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Moehs Iberica

09

Granules India Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
Granules India

10

Siegfried AG

Switzerland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSiegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.

Flag Switzerland
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Company Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

Veranova Lp

U.S.A
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2020-01-28

Pay. Date : 2020-01-21

DMF Number : 22442

Submission : 2009-01-27

Status : Active

Type : II

Veranova

02

Veranova Lp

U.S.A
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2023-11-21

Pay. Date : 2023-10-12

DMF Number : 38874

Submission : 2023-10-20

Status : Active

Type : II

Veranova

03

Noramco Llc

U.S.A
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNoramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.

Flag U.S.A
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2021-12-30

Pay. Date : 2021-11-18

DMF Number : 35645

Submission : 2021-11-23

Status : Active

Type : II

Noramco

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 42282

Submission : 2025-07-11

Status : Active

Type : II

Cohance

05

Alkem Laboratories Ltd

India

USDMF

arrow
PEGS Boston Summit
Not Confirmed

05

Alkem Laboratories Ltd

India
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2025-04-21

Pay. Date : 2025-04-08

DMF Number : 38667

Submission : 2023-08-03

Status : Active

Type : II

blank

06

Alkem Laboratories Ltd

India

USDMF

arrow
PEGS Boston Summit
Not Confirmed

06

Alkem Laboratories Ltd

India
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36325

Submission : 2021-10-25

Status : Active

Type : II

blank

07

PEGS Boston Summit
Not Confirmed

07

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 20103

Submission : 2006-12-29

Status : Inactive

Type : II

blank

08

Chattem Chemicals Inc

U.S.A

USDMF

arrow
PEGS Boston Summit
Not Confirmed

08

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-07-02

Pay. Date : 2018-05-22

DMF Number : 32289

Submission : 2018-05-18

Status : Active

Type : II

blank

09

Specgx Llc

Ireland

USDMF

arrow
PEGS Boston Summit
Not Confirmed

09

Specgx Llc

Ireland
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-07-28

Pay. Date : 2020-06-03

DMF Number : 34823

Submission : 2020-05-29

Status : Active

Type : II

blank

10

Specgx Llc

Ireland

USDMF

arrow
PEGS Boston Summit
Not Confirmed

10

Specgx Llc

Ireland
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 32210

Submission : 2017-11-22

Status : Inactive

Type : II

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

Alkem Laboratories

India
PEGS Boston Summit
Not Confirmed
arrow

Alkem Laboratories

India
arrow
PEGS Boston Summit
Not Confirmed

Lisdexamfetamine Dimesylate IH

Date of Issue : 2025-09-24

Valid Till : 2028-09-23

Written Confirmation Number : WC-0385

Address of the Firm : Survey No. -85 to 88, N.H. No. 8, Naugama,At & Post-Mandva, Tal. -Ankleshwar, Di...

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Lisdexamfetamine Dimesylate IH

Date of Issue : 2025-08-08

Valid Till : 2028-07-28

Written Confirmation Number : WC-0046

Address of the Firm : E-21, MIDC, Indt. Estate, Mahad-402 309, Taluka: Mahad, District: Raigad, Mahara...

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Lisdexamphetamine Diadipate IH

Date of Issue : 2025-08-08

Valid Till : 2028-07-28

Written Confirmation Number : WC-0046

Address of the Firm : E-21, MIDC, Indt. Estate, Mahad-402 309, Taluka: Mahad, District: Raigad, Mahara...

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Lisdexamfetamine Dimesylate IH

Date of Issue : 2022-06-03

Valid Till : 2025-05-27

Written Confirmation Number : WC-003

Address of the Firm : Village Bhagwanpur, Barwala Road, Derabassi -140507, District S.A.S Nagar (Mohal...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 49812-0307

Start Marketing Date : 2026-01-08

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Veranova

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 49812-0186

Start Marketing Date : 2012-01-01

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Veranova

03

Noramco, LLC

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNoramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.

Flag U.S.A
Digital Content Digital Content

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 51634-2058

Start Marketing Date : 2021-12-10

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Noramco

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 62207-024

Start Marketing Date : 2024-10-28

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Granules India

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 50683-0660

Start Marketing Date : 2025-05-05

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 59116-3010

Start Marketing Date : 2012-10-26

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 59116-3011

Start Marketing Date : 2013-07-02

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 59116-3013

Start Marketing Date : 2016-10-14

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 59116-3012

Start Marketing Date : 2014-01-01

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

10

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

LISDEXAMFETAMINE DIMESYLATE

NDC Package Code : 53834-401

Start Marketing Date : 2023-10-30

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Veranova

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content

Lisdexamfetamine Dimesylate

About the Company : Veranova is a global leader in developing and manufacturing specialist and complex APIs for pharma and biotech customers, with over 50 years of experience supporting the healthcare...

Veranova is a global leader in developing and manufacturing specialist and complex APIs for pharma and biotech customers, with over 50 years of experience supporting the healthcare industry and building trusted customer relationships. Operating in two divisions-Generics and Originators-it offers tailored services for every stage of the drug development lifecycle. Macfarlan Smith Limited trades as Veranova in the United Kingdom. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Veranova

02

Noramco

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNoramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.

Flag U.S.A
Digital Content Digital Content

Lisdexamfetamine Dimesylate

About the Company : Noramco, founded in 1979, specializes in developing and manufacturing APIs for opioid and non-opioid products. It excels in controlled substance development, offering supply-chain ...

Noramco, founded in 1979, specializes in developing and manufacturing APIs for opioid and non-opioid products. It excels in controlled substance development, offering supply-chain integration, efficient API routes, analytical data, stability studies, regulatory support, formulation-friendly particle sizes, extended technical packages, DEA-compliant security, and scalable production from kilos to multi-tons. Noramco ensures world-class supply security for Schedule I to III controlled substances. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Noramco

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

Flag India
Digital Content Digital Content

Lisdexamfetamine

About the Company : Supriya Lifescience Limited, established in 1987 and headquartered in Mumbai, is a globally recognized, technology-driven manufacturer of APIs, CDMO, and formulations. Its faciliti...

Supriya Lifescience Limited, established in 1987 and headquartered in Mumbai, is a globally recognized, technology-driven manufacturer of APIs, CDMO, and formulations. Its facilities in Lote and Ambernath are approved by USFDA, EUGMP, Health Canada, and other agencies. Specializing in antihistamines, antiallergics, vitamins, anesthetics, and anti-asthmatics, Supriya serves 1500+ customers in over 86 countries, with 15+ USDMFs, 10+ CEPs, and a 1050 KL manufacturing capacity. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Supriya

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Flag India
Digital Content Digital Content

Lisdexamfetamine Dimesylate

About the Company : Cohance Lifesciences is a leading CDMO and API platform delivering products and services across the full molecule lifecycle, from development to commercialization. With strong expe...

Cohance Lifesciences is a leading CDMO and API platform delivering products and services across the full molecule lifecycle, from development to commercialization. With strong expertise in complex chemistries, we provide end-to-end CDMO solutions to global innovators. As a global API player, we serve customers in nearly 60 countries with 80+ molecules, supported by robust R&D, regulatory capabilities, and advanced manufacturing infrastructure, including strong backward-integrated pellet manufacturing. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Cohance

05

Fermion Oy

Finland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content

Lisdexamfetamine

About the Company : Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. Its API portfolio inc...

Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. Its API portfolio includes over 30 generic APIs and more than 10 NCEs, with two manufacturing sites and R&D facilities in Finland. Fermion has expanded capabilities in HPAPI production. Drug product CMO services cover hormonal and non-hormonal semi-solids, cytotoxic oral solids, and packaging, supported by three manufacturing sites and one packaging center under Orion. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
fermion

06

Temad Co

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTemad- We think of world-class quality.

Flag Iran
Digital Content Digital Content

Lisdexamfetamine Dimesylate

About the Company : Temad Co., established in 1997, is one of Iran's largest API producers and an innovative manufacturer of narcotic and non-narcotic products in the Middle East. It complies with Ira...

Temad Co., established in 1997, is one of Iran's largest API producers and an innovative manufacturer of narcotic and non-narcotic products in the Middle East. It complies with Iranian GMP and international standards like ISO 9001/14001/17025/45001 and OHSAS 18001. Temad manufactures over 115 pharmaceutical products, meeting GMP and WHO standards, and exports to 45 countries worldwide. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Temad

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMalladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.

Flag India
Digital Content Digital Content

Lisdexamfetamine

About the Company : Malladi Drugs & Pharmaceuticals Ltd, founded in 1980 by Mr. M L N Sastry, is a leader in manufacturing ephedrine and pseudoephedrine salts. It is now the top API manufacturer in th...

Malladi Drugs & Pharmaceuticals Ltd, founded in 1980 by Mr. M L N Sastry, is a leader in manufacturing ephedrine and pseudoephedrine salts. It is now the top API manufacturer in the cough and cold segment, with strong presence in antihistamines, anti-convulsants, anti-depressants, and anxiolytics. Malladi exports to around 60 countries, with over 85% revenue from exports, and its facilities are approved by FDA, EDQM, KFDA, TGA, and other agencies. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Malladi

08

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content

Lisdexamfetamine Dimesylate

About the Company : Since 1962, MOEHS has produced high-quality Active Pharmaceutical Ingredients (APIs) for the global market. With decades of technical expertise, Moehs Group delivers pharmaceutical...

Since 1962, MOEHS has produced high-quality Active Pharmaceutical Ingredients (APIs) for the global market. With decades of technical expertise, Moehs Group delivers pharmaceutical, veterinary, agrochemical, nutraceutical, cosmetic, and fine chemical products. Our facilities meet the highest standards, including GMP, ICH, FDA, and TGA approvals, ensuring reliable and safe manufacturing. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only.
Moehs Iberica

09

Siegfried AG

Switzerland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSiegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.

Flag Switzerland
Digital Content Digital Content

Lisdexamfetamine Dimesylate

About the Company : Siegfried is a global Contract Development and Manufacturing Organization providing integrated services for pharmaceutical ingredients & finished dosage forms. With 13 production s...

Siegfried is a global Contract Development and Manufacturing Organization providing integrated services for pharmaceutical ingredients & finished dosage forms. With 13 production sites across three continents, we support customers across the full value chain, from process development and optimization to manufacturing, packaging, and logistics. Founded in 1873 in Zofingen, Switzerland, Siegfried combines deep pharmaceutical and chemical expertise with global scale to deliver high-quality medicines reliably to patients worldwide. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

10

Alkem Laboratories

India
PEGS Boston Summit
Not Confirmed
arrow

Alkem Laboratories

India
arrow
PEGS Boston Summit
Not Confirmed

Lisdexamfetamine Dimesylate

About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...

Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 40 countries. 29% of our revenue is generated via offshore sales and it has consistently been ranked amongst the top ten pharmaceutical companies in India. They have 20 manufacturing facilities at multiple locations in India and the United States of America.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

FDA approved Lisdexamfetamine Dimesylate Capsules, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.


Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse-Generic

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 30, 2025

Granules India

01

Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : FDA approved Lisdexamfetamine Dimesylate Capsules, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.

Product Name : Vyvanse-Generic

Product Type : Controlled Substance

Upfront Cash : Inapplicable

January 30, 2025

Granules India

Details:

FDA approved Lisdexamfetamine Dimesylate Tablets, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.


Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse-Generic

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 17, 2024

Granules India

02

Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : FDA approved Lisdexamfetamine Dimesylate Tablets, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.

Product Name : Vyvanse-Generic

Product Type : Controlled Substance

Upfront Cash : Inapplicable

December 17, 2024

Granules India

Details:

Centanafadine is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.


Lead Product(s): Centanafadine,Methylphenidate,Lisdexamfetamine Dimesylate

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 02, 2026

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Centanafadine is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 02, 2026

blank

Details:

Lisdexamfetamine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.


Lead Product(s): Lisdexamfetamine Dimesylate

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 01, 2025

blank

04

Humanis

Turkey
arrow
PEGS Boston Summit
Not Confirmed

Humanis

Turkey
arrow
PEGS Boston Summit
Not Confirmed

Details : Lisdexamfetamine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 01, 2025

blank

Details:

Lisdexamfetamine dimesylate capsules, for oral use is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder and Moderate to Severe Binge Eating Disorder (BED) in adults.


Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse-Generic

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 06, 2023

blank

05

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Lisdexamfetamine dimesylate capsules, for oral use is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder and Moderate to Severe Binge Eating Disorder (BED) in adults.

Product Name : Vyvanse-Generic

Product Type : Controlled Substance

Upfront Cash : Inapplicable

September 06, 2023

blank

Details:

Lisdexamfetamine Dimesylate Capsules are a federally controlled substance (CII) used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and other indications and currently are on the FDA's drug shortage list.


Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse-Generic

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 31, 2023

blank

06

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Lisdexamfetamine Dimesylate Capsules are a federally controlled substance (CII) used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and other indications and currently are on the FDA's drug shortage list.

Product Name : Vyvanse-Generic

Product Type : Controlled Substance

Upfront Cash : Inapplicable

August 31, 2023

blank

Details:

Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bulimia Nervosa.


Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Controlled Substance

Sponsor: Nova Scotia Health Authority

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 12, 2018

blank

07

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bulimia Nervosa.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

January 12, 2018

blank
  • Development Update

Details:

Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.


Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Controlled Substance

Sponsor: SHIRE PLC

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 09, 2017

blank

08

JPM van Stralen Medicine Professional

Country
arrow
PEGS Boston Summit
Not Confirmed

JPM van Stralen Medicine Professional

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

November 09, 2017

blank
  • Development Update

Details:

Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.


Lead Product(s): Lisdexamfetamine Dimesylate,Guanfacine

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Controlled Substance

Sponsor: SHIRE PLC

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 07, 2017

blank

09

King's College London

Country
arrow
PEGS Boston Summit
Not Confirmed

King's College London

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

November 07, 2017

blank

Details:

Vyvanse (Lisdexamfetamine Dimesylate) is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.


Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 24, 2017

blank

10

SHIRE PLC

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

SHIRE PLC

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

Details : Vyvanse (Lisdexamfetamine Dimesylate) is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

Product Name : Vyvanse

Product Type : Controlled Substance

Upfront Cash : Inapplicable

August 24, 2017

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

CAS Number : 819871-13-1

End Use API : Lisdexamfetamine Dimesylate

About The Company : Cohance Lifesciences is a leading CDMO and API platform delivering products and services across the full molecule lifecycle, from development to commercializati...

Cohance

02

Suanfarma

Spain
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSuanfarma, at the Core of a Better Life.

CAS Number : 2592-19-0

End Use API : Lisdexamfetamine Dimesylate

About The Company : Suanfarma is a B2B life sciences company focused on developing, manufacturing, and distributing high-quality ingredients for the pharmaceutical industry in an i...

Suanfarma

03

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 16251-45-9

End Use API : Lisdexamfetamine Dimesylate

About The Company : Anvitha Life Care Private Limited, founded in 2016 by Dr. T. Prakasam and a team of experienced scientists and technocrats with over 80 years of combined expert...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAthena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

Flag France
Digital Content Digital Content

Regulatory Info :

Registration Country : France

Lisdexamfetamine Dimesylate

Brand Name : Lisdexamfetamine

Dosage Form : Oral-Dispersible Table...

Dosage Strength : 10MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : France

Athena Company Banner

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAthena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

Flag France
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Oral-Dispersible Table...

Dosage Strength : 10MG

Brand Name : Lisdexamfetamine

Approval Date :

Application Number :

Registration Country : France

Athena Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAthena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

Flag France
Digital Content Digital Content

Regulatory Info :

Registration Country : France

Lisdexamfetamine Dimesylate

Brand Name : Lisdexamfetamine

Dosage Form : Oral-Dispersible Table...

Dosage Strength : 70MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : France

Athena Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAthena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

Flag France
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Oral-Dispersible Table...

Dosage Strength : 70MG

Brand Name : Lisdexamfetamine

Approval Date :

Application Number :

Registration Country : France

Athena Company Banner

03

Temad Co

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTemad- We think of world-class quality.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Lisdexamfetamine Dimesylate

Brand Name :

Dosage Form : Syrup

Dosage Strength : 10MG/1ML

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

Temad

03

Temad Co

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTemad- We think of world-class quality.

Flag Iran
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Syrup

Dosage Strength : 10MG/1ML

Brand Name :

Approval Date :

Application Number :

Registration Country : Iran

Temad

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Lisdexamfetamine Dimesylate

Brand Name : Lisdexamfetamine Dimes...

Dosage Form : Immediate Release Chew...

Dosage Strength : 20MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Granules India

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Immediate Release Chew...

Dosage Strength : 20MG

Brand Name : Lisdexamfetamine Dimes...

Approval Date :

Application Number :

Registration Country : India

Granules India

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Lisdexamfetamine Dimesylate

Brand Name : Lisdexamfetamine Dimes...

Dosage Form : Immediate Release Chew...

Dosage Strength : 30MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Granules India

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Immediate Release Chew...

Dosage Strength : 30MG

Brand Name : Lisdexamfetamine Dimes...

Approval Date :

Application Number :

Registration Country : India

Granules India

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Lisdexamfetamine Dimesylate

Brand Name : Lisdexamfetamine Dimes...

Dosage Form : Immediate Release Chew...

Dosage Strength : 40MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Granules India

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Immediate Release Chew...

Dosage Strength : 40MG

Brand Name : Lisdexamfetamine Dimes...

Approval Date :

Application Number :

Registration Country : India

Granules India

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Lisdexamfetamine Dimesylate

Brand Name : Lisdexamfetamine Dimes...

Dosage Form : Immediate Release Chew...

Dosage Strength : 50MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Granules India

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Immediate Release Chew...

Dosage Strength : 50MG

Brand Name : Lisdexamfetamine Dimes...

Approval Date :

Application Number :

Registration Country : India

Granules India

08

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Lisdexamfetamine Dimesylate

Brand Name : Lisdexamfetamine Dimes...

Dosage Form : Immediate Release Caps...

Dosage Strength : 10MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Granules India

08

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Immediate Release Caps...

Dosage Strength : 10MG

Brand Name : Lisdexamfetamine Dimes...

Approval Date :

Application Number :

Registration Country : India

Granules India

09

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Lisdexamfetamine Dimesylate

Brand Name : Lisdexamfetamine Dimes...

Dosage Form : Immediate Release Caps...

Dosage Strength : 20MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Granules India

09

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Immediate Release Caps...

Dosage Strength : 20MG

Brand Name : Lisdexamfetamine Dimes...

Approval Date :

Application Number :

Registration Country : India

Granules India

10

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Lisdexamfetamine Dimesylate

Brand Name : Lisdexamfetamine Dimes...

Dosage Form : Immediate Release Caps...

Dosage Strength : 30MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Granules India

10

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Packaging :

Regulatory Info :

Lisdexamfetamine Dimesylate

Dosage : Immediate Release Caps...

Dosage Strength : 30MG

Brand Name : Lisdexamfetamine Dimes...

Approval Date :

Application Number :

Registration Country : India

Granules India
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - 10MG

USFDA APPLICATION NUMBER - 21977

read-more

DOSAGE - CAPSULE;ORAL - 20MG

USFDA APPLICATION NUMBER - 21977

read-more

DOSAGE - CAPSULE;ORAL - 30MG

USFDA APPLICATION NUMBER - 21977

read-more

DOSAGE - CAPSULE;ORAL - 40MG

USFDA APPLICATION NUMBER - 21977

read-more

DOSAGE - CAPSULE;ORAL - 50MG

USFDA APPLICATION NUMBER - 21977

read-more

DOSAGE - CAPSULE;ORAL - 60MG

USFDA APPLICATION NUMBER - 21977

read-more

DOSAGE - CAPSULE;ORAL - 70MG

USFDA APPLICATION NUMBER - 21977

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Granulation

read-more
read-more

Lubricants & Glidants

read-more
read-more

Empty Capsules

read-more
read-more

Coating Systems & Additives

read-more
read-more

Parenteral

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Emulsifying Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Solubilizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF DOSSIERS

read-more
read-more
26 Aug 2023

Reply

26 Aug 2023

Reply text-arrow

Reply Comment (4)

26 Aug 2023

PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 608137-33-3 / Lisdexamfetamine Dimesylate API manufacturers, exporters & distributors?

Lisdexamfetamine Dimesylate manufacturers, exporters & distributors 1

21

PharmaCompass offers a list of Lisdexamfetamine Dimesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Lisdexamfetamine Dimesylate manufacturer or Lisdexamfetamine Dimesylate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lisdexamfetamine Dimesylate manufacturer or Lisdexamfetamine Dimesylate supplier.

API | Excipient name

Lisdexamfetamine Dimesylate

Synonyms

Vyvanse, 608137-33-3, Nrp-104, Lisdexamfetamine mesilate, Spd489, Tyvense

Cas Number

608137-33-3

Unique Ingredient Identifier (UNII)

SJT761GEGS

About Lisdexamfetamine Dimesylate

A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

Vyvanse Manufacturers

A Vyvanse manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vyvanse, including repackagers and relabelers. The FDA regulates Vyvanse manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vyvanse API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Vyvanse manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Vyvanse Suppliers

A Vyvanse supplier is an individual or a company that provides Vyvanse active pharmaceutical ingredient (API) or Vyvanse finished formulations upon request. The Vyvanse suppliers may include Vyvanse API manufacturers, exporters, distributors and traders.

click here to find a list of Vyvanse suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Vyvanse USDMF

A Vyvanse DMF (Drug Master File) is a document detailing the whole manufacturing process of Vyvanse active pharmaceutical ingredient (API) in detail. Different forms of Vyvanse DMFs exist exist since differing nations have different regulations, such as Vyvanse USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Vyvanse DMF submitted to regulatory agencies in the US is known as a USDMF. Vyvanse USDMF includes data on Vyvanse's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vyvanse USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Vyvanse suppliers with USDMF on PharmaCompass.

Vyvanse WC

A Vyvanse written confirmation (Vyvanse WC) is an official document issued by a regulatory agency to a Vyvanse manufacturer, verifying that the manufacturing facility of a Vyvanse active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Vyvanse APIs or Vyvanse finished pharmaceutical products to another nation, regulatory agencies frequently require a Vyvanse WC (written confirmation) as part of the regulatory process.

click here to find a list of Vyvanse suppliers with Written Confirmation (WC) on PharmaCompass.

Vyvanse NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vyvanse as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Vyvanse API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Vyvanse as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Vyvanse and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vyvanse NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Vyvanse suppliers with NDC on PharmaCompass.

Vyvanse GMP

Vyvanse Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Vyvanse GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Vyvanse GMP manufacturer or Vyvanse GMP API supplier for your needs.

Vyvanse CoA

A Vyvanse CoA (Certificate of Analysis) is a formal document that attests to Vyvanse's compliance with Vyvanse specifications and serves as a tool for batch-level quality control.

Vyvanse CoA mostly includes findings from lab analyses of a specific batch. For each Vyvanse CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Vyvanse may be tested according to a variety of international standards, such as European Pharmacopoeia (Vyvanse EP), Vyvanse JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vyvanse USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty